Strategic Trends in Private Equity & Venture Capital Funding for Healthcare - Companies Must Embrace New Funding Sources - Re...
December 07 2016 - 3:19PM
Business Wire
Research and Markets has announced the addition of the
"Strategic Trends in Private Equity and Venture Capital Funding for
Healthcare" report to their offering.
Although the life sciences industry remains an attractive
investment area, the healthcare sector has seen a decline in
venture investments, particularly for early-stage investments, as
pricing pressures, stringent regulations, rising development costs,
reimbursement issues, and declining R&D productivity have
proved significant barriers.
The continued decline in R&D productivity is one of the most
important challenges the healthcare industry is facing at a global
level. Blockbuster therapies, for example, have become increasingly
rare, and many drugs continue to face reimbursement challenges in
key markets, resulting in declining revenues for companies.
The accumulating evidence of the decline in R&D productivity
adds to the uncertainty associated with innovation in the
healthcare industry, which in turn reduces the attractiveness of
the field for investment.
Despite this, a recent surge in the approval of innovative
drugs, coupled with reports of companies having been more
successful in the final stages of clinical testing, seems to point
towards a brighter future in this regard. Indeed, the number of new
molecular entities launched globally in 2014 reached a 17-year high
of 46.
If investments from private equity and venture capital (VC)
firms in the healthcare industry continue to decrease
significantly, it could have serious and wide-ranging consequences
not just in the healthcare sector, but in wider economies. Fewer
treatment options, a sharp decline in innovation, and significant
financial constraints for companies in the sector could result in
job losses, important projects being abandoned, and company
relocations or complete shutdowns.
Companies Mentioned:
- Adaptimmune Therapeutics
- Aimmune Therapeutics
- Apax Partners
- Axovant Sciences
- Bain Capital Private Equity
- Blueprint Medicines
- Flagship Ventures
- Global Blood Therapeutics
- KKR & Co
- Kleiner Perkins Caufield & Byers
- (10+ Others)
Key Topics Covered:
1 Table of Contents
2 Introduction
3 Global Trends in Private Equity and Venture Capital
Investments in the Healthcare Industry
4 US Private Equity and Venture Capital Industry Dynamics
5 Equity Offerings in the Healthcare Sector, Value and Volume,
2006-2015
6 Private Equity Firms, Company Drill-Downs
7 Venture Capital Firms, Company Drill-Downs
8 Future Outlook
9 Conclusions
For more information about this report visit
http://www.researchandmarkets.com/research/grz9sm/strategic_trends
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161207006208/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Venture Capital, Private
Equity